DEK and arthritic joint disease: As DEK-targeting aptamers reduce NET formation in zymosan-injected joints and human peripheral blood neutrophils, we conclude that targeting DEK in the setting of arthritis, especially with aptamers, may serve as a viable therapeutic strategy.